open access

Vol 12, No 6 (2016)
Review paper
Published online: 2017-06-02
Get Citation

Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer

Roman Dubiański, Agnieszka Jagiełło-Gruszfeld, Zbigniew Nowecki
DOI: 10.5603/OCP.2016.0017
·
Oncol Clin Pract 2016;12(6):209-214.

open access

Vol 12, No 6 (2016)
REVIEW ARTICLES
Published online: 2017-06-02

Abstract

Breast cancer remains the most frequent cancer among women in Poland with malignancies, despite significant improvement in early detection and treatment. In oestrogen receptor-positive breast cancers activation of the CDK4/CDK6/E2F axis is very common, and one of the mechanisms of action of the endocrine therapies is the suppression of CDK4 and CDK6 activity. The inhibition of CDKs is an important target for novel agents. This article concentrates on two CDK4/6 inhibitors, which showed promising efficacy in recently published studies: palbociclib and ribociclib. The phase 3 studies with palbociclib and ribociclib produced practice-changing results, improving the progression-free survival in the first-line setting in ER-positive HER2-negative advanced breast cancer when added to standard endocrine therapy.

Abstract

Breast cancer remains the most frequent cancer among women in Poland with malignancies, despite significant improvement in early detection and treatment. In oestrogen receptor-positive breast cancers activation of the CDK4/CDK6/E2F axis is very common, and one of the mechanisms of action of the endocrine therapies is the suppression of CDK4 and CDK6 activity. The inhibition of CDKs is an important target for novel agents. This article concentrates on two CDK4/6 inhibitors, which showed promising efficacy in recently published studies: palbociclib and ribociclib. The phase 3 studies with palbociclib and ribociclib produced practice-changing results, improving the progression-free survival in the first-line setting in ER-positive HER2-negative advanced breast cancer when added to standard endocrine therapy.

Get Citation

Keywords

CDK4/6 inhibitor, breast cancer, palbociclib, ribociclib, abemaciclib

About this article
Title

Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 6 (2016)

Article type

Review paper

Pages

209-214

Published online

2017-06-02

DOI

10.5603/OCP.2016.0017

Bibliographic record

Oncol Clin Pract 2016;12(6):209-214.

Keywords

CDK4/6 inhibitor
breast cancer
palbociclib
ribociclib
abemaciclib

Authors

Roman Dubiański
Agnieszka Jagiełło-Gruszfeld
Zbigniew Nowecki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl